FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901231685> ?p ?o ?g. }

• W2901231685 endingPage "ix136" @default.
• W2901231685 startingPage "ix136" @default.
• W2901231685 abstract "Background: Bone pain resulting from myeloma bone lesions and corticosteroid used in treatment regimens tend to impair performance status (PS) and decrease muscle mass in myeloma patients. One of the important issues when treating myeloma patients is the maintenance of muscle mass. Methods: Participants of this study were patients newly diagnosed with symptomatic multiple myeloma at Tokushima University Hospital from 2003 to 2016. Patients who had undergone computed tomography including the lumbar spine within one year of the initial diagnosis were chosen and analyzed retrospectively. A functional tool, AquariousNET, image viewer was used with manual trace method to measure the cross-sectional area of the psoas and gluteal muscles at the L3 level. This study was approved by the internal review board of the Tokushima University (permission number 2756-1). Results: 37 patients (17 men and 20 women) were included in the analysis with a mean age of 62.1±10.6 (median 65) years. High-dose dexamethasone (HDD), including vincristine, doxorubicin and dexamethasone (VAD) therapy, melphalan combined with prednisolone (MP), immunomodulatory drugs, and proteasome inhibitor (PI) were used as induction chemotherapy in 15, 6, 2, and 14 patients, respectively. Among them, 1, 1, 0, and 2 patients had a PS score of 3–4, while 6, 4, 0, and 5 patients had a bone scale score of 3. Within 6 months of treatment initiation, patients in PI-based treatment groups had a tendency to retain more muscle mass in the psoas muscle (99.3±22%) when compared to baseline, than did the HDD based treatment group (87.94±9.93%). Gluteal muscles were significantly decreased in the HDD-based treatment group compared with the PI-based treatment group (85.84±12.63% vs. 109.42±17.82%; p < 0.05) within 6 months. The muscle mass values in HDD/MP/PI groups 6-12 months after initial chemotherapy were 85.99 ±13.46/75.4±13.2/92.43±18.98% (psoas muscle) and, 87.81±16.08/89.2±20.1/96.66±9.3% (gluteal muscle) compared to baseline. All patients in the HDD-based treatment group had a decrease in muscle mass, whereas 4 of 14 patients in the PI-based treatment group had increase in the muscle mass 6-12 months after initial chemotherapy. Conclusions: Proteasome inhibitor may have the ability to reduce the muscle mass loss during treatment in myeloma patients. Legal entity responsible for the study: Shingen Nakamura. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
• W2901231685 created "2018-11-29" @default.
• W2901231685 creator A5002719065 @default.
• W2901231685 creator A5006158144 @default.
• W2901231685 creator A5010107690 @default.
• W2901231685 creator A5025061047 @default.
• W2901231685 creator A5028862201 @default.
• W2901231685 creator A5034476246 @default.
• W2901231685 creator A5036954013 @default.
• W2901231685 creator A5044951286 @default.
• W2901231685 creator A5055578834 @default.
• W2901231685 creator A5077492679 @default.
• W2901231685 creator A5088707445 @default.
• W2901231685 date "2018-11-01" @default.
• W2901231685 modified "2023-09-27" @default.
• W2901231685 title "Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma" @default.
• W2901231685 doi "https://doi.org/10.1093/annonc/mdy444.024" @default.
• W2901231685 hasPublicationYear "2018" @default.
• W2901231685 type Work @default.
• W2901231685 sameAs 2901231685 @default.
• W2901231685 citedByCount "0" @default.
• W2901231685 crossrefType "journal-article" @default.
• W2901231685 hasAuthorship W2901231685A5002719065 @default.
• W2901231685 hasAuthorship W2901231685A5006158144 @default.
• W2901231685 hasAuthorship W2901231685A5010107690 @default.
• W2901231685 hasAuthorship W2901231685A5025061047 @default.
• W2901231685 hasAuthorship W2901231685A5028862201 @default.
• W2901231685 hasAuthorship W2901231685A5034476246 @default.
• W2901231685 hasAuthorship W2901231685A5036954013 @default.
• W2901231685 hasAuthorship W2901231685A5044951286 @default.
• W2901231685 hasAuthorship W2901231685A5055578834 @default.
• W2901231685 hasAuthorship W2901231685A5077492679 @default.
• W2901231685 hasAuthorship W2901231685A5088707445 @default.
• W2901231685 hasBestOaLocation W29012316851 @default.
• W2901231685 hasConcept C126322002 @default.
• W2901231685 hasConcept C126894567 @default.
• W2901231685 hasConcept C141071460 @default.
• W2901231685 hasConcept C2776364478 @default.
• W2901231685 hasConcept C2776694085 @default.
• W2901231685 hasConcept C2776715498 @default.
• W2901231685 hasConcept C2776755627 @default.
• W2901231685 hasConcept C2778684742 @default.
• W2901231685 hasConcept C2779429289 @default.
• W2901231685 hasConcept C2780401358 @default.
• W2901231685 hasConcept C71924100 @default.
• W2901231685 hasConcept C90924648 @default.
• W2901231685 hasConceptScore W2901231685C126322002 @default.
• W2901231685 hasConceptScore W2901231685C126894567 @default.
• W2901231685 hasConceptScore W2901231685C141071460 @default.
• W2901231685 hasConceptScore W2901231685C2776364478 @default.
• W2901231685 hasConceptScore W2901231685C2776694085 @default.
• W2901231685 hasConceptScore W2901231685C2776715498 @default.
• W2901231685 hasConceptScore W2901231685C2776755627 @default.
• W2901231685 hasConceptScore W2901231685C2778684742 @default.
• W2901231685 hasConceptScore W2901231685C2779429289 @default.
• W2901231685 hasConceptScore W2901231685C2780401358 @default.
• W2901231685 hasConceptScore W2901231685C71924100 @default.
• W2901231685 hasConceptScore W2901231685C90924648 @default.
• W2901231685 hasLocation W29012316851 @default.
• W2901231685 hasOpenAccess W2901231685 @default.
• W2901231685 hasPrimaryLocation W29012316851 @default.
• W2901231685 hasRelatedWork W1968709730 @default.
• W2901231685 hasRelatedWork W2007459874 @default.
• W2901231685 hasRelatedWork W2029663981 @default.
• W2901231685 hasRelatedWork W2032575512 @default.
• W2901231685 hasRelatedWork W2080555893 @default.
• W2901231685 hasRelatedWork W2410396614 @default.
• W2901231685 hasRelatedWork W2417317702 @default.
• W2901231685 hasRelatedWork W2465225878 @default.
• W2901231685 hasRelatedWork W4252840856 @default.
• W2901231685 hasRelatedWork W2172104866 @default.
• W2901231685 hasVolume "29" @default.
• W2901231685 isParatext "false" @default.
• W2901231685 isRetracted "false" @default.
• W2901231685 magId "2901231685" @default.
• W2901231685 workType "article" @default.